Androgenetic Alopecia

An Update of Treatment Options

Yanna Kelly, Aline Blanco, Antonella Tosti

Research output: Contribution to journalReview article

39 Citations (Scopus)

Abstract

Androgenetic alopecia (AGA) is characterized by a non-scarring progressive miniaturization of the hair follicle in predisposed men and women with a pattern distribution. Although AGA is a very prevalent condition, approved therapeutic options are limited. This article discusses the current treatment alternatives including their efficacy, safety profile, and quality of evidence. Finasteride and minoxidil for male androgenetic alopecia and minoxidil for female androgenetic alopecia still are the therapeutic options with the highest level evidence. The role of antiandrogens for female patients, the importance of adjuvant therapies, as well as new drugs and procedures are also addressed.

Original languageEnglish (US)
Pages (from-to)1349-1364
Number of pages16
JournalDrugs
Volume76
Issue number14
DOIs
StatePublished - Sep 1 2016

Fingerprint

Alopecia
Minoxidil
Finasteride
Miniaturization
Androgen Antagonists
Hair Follicle
Therapeutics
Safety
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Androgenetic Alopecia : An Update of Treatment Options. / Kelly, Yanna; Blanco, Aline; Tosti, Antonella.

In: Drugs, Vol. 76, No. 14, 01.09.2016, p. 1349-1364.

Research output: Contribution to journalReview article

Kelly, Yanna ; Blanco, Aline ; Tosti, Antonella. / Androgenetic Alopecia : An Update of Treatment Options. In: Drugs. 2016 ; Vol. 76, No. 14. pp. 1349-1364.
@article{1744c44b404f467b913decb0b2e9a1a7,
title = "Androgenetic Alopecia: An Update of Treatment Options",
abstract = "Androgenetic alopecia (AGA) is characterized by a non-scarring progressive miniaturization of the hair follicle in predisposed men and women with a pattern distribution. Although AGA is a very prevalent condition, approved therapeutic options are limited. This article discusses the current treatment alternatives including their efficacy, safety profile, and quality of evidence. Finasteride and minoxidil for male androgenetic alopecia and minoxidil for female androgenetic alopecia still are the therapeutic options with the highest level evidence. The role of antiandrogens for female patients, the importance of adjuvant therapies, as well as new drugs and procedures are also addressed.",
author = "Yanna Kelly and Aline Blanco and Antonella Tosti",
year = "2016",
month = "9",
day = "1",
doi = "10.1007/s40265-016-0629-5",
language = "English (US)",
volume = "76",
pages = "1349--1364",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "14",

}

TY - JOUR

T1 - Androgenetic Alopecia

T2 - An Update of Treatment Options

AU - Kelly, Yanna

AU - Blanco, Aline

AU - Tosti, Antonella

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Androgenetic alopecia (AGA) is characterized by a non-scarring progressive miniaturization of the hair follicle in predisposed men and women with a pattern distribution. Although AGA is a very prevalent condition, approved therapeutic options are limited. This article discusses the current treatment alternatives including their efficacy, safety profile, and quality of evidence. Finasteride and minoxidil for male androgenetic alopecia and minoxidil for female androgenetic alopecia still are the therapeutic options with the highest level evidence. The role of antiandrogens for female patients, the importance of adjuvant therapies, as well as new drugs and procedures are also addressed.

AB - Androgenetic alopecia (AGA) is characterized by a non-scarring progressive miniaturization of the hair follicle in predisposed men and women with a pattern distribution. Although AGA is a very prevalent condition, approved therapeutic options are limited. This article discusses the current treatment alternatives including their efficacy, safety profile, and quality of evidence. Finasteride and minoxidil for male androgenetic alopecia and minoxidil for female androgenetic alopecia still are the therapeutic options with the highest level evidence. The role of antiandrogens for female patients, the importance of adjuvant therapies, as well as new drugs and procedures are also addressed.

UR - http://www.scopus.com/inward/record.url?scp=84983391627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983391627&partnerID=8YFLogxK

U2 - 10.1007/s40265-016-0629-5

DO - 10.1007/s40265-016-0629-5

M3 - Review article

VL - 76

SP - 1349

EP - 1364

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 14

ER -